https://scholars.lib.ntu.edu.tw/handle/123456789/510798
標題: | Association between weight change during initial chemotherapy and clinical outcome in dogs with multicentric lymphoma | 作者: | Lee, Wei-Shan Lee, Jih-Jong TAI-CHING LIAO Kao, Chia-Lien SHANG-LIN WANG JIH-JONG LEE |
關鍵字: | canine; neoplasm; oncology; outcome; prognosis | 公開日期: | 12-七月-2020 | 來源出版物: | Veterinary and comparative oncology | 摘要: | The majority of the known prognostic factors in dogs with lymphoma have been evaluated before treatment commences or at the time of diagnosis. Prognostic factors evaluated during the initial phase of treatment are less described but may provide important clinical information. In this retrospective study, eighty-two canine lymphoma patients were categorized according to the weight change between diagnosis and after 5 weeks of chemotherapy. Dogs that gained >5% or lost > 5% of initial body weight were categorized as increased- or decreased-weight groups, respectively. Those in which weight changed less than 5% were categorized as the maintained-weight group. The median progression-free survival (PFS) in the increased-weight group, maintained-weight group, and decreased-weight group was 226, 256, and 129 days, respectively. The decreased-weight group had significantly shorter PFS than the increased and maintained groups (P = 0.023, P = 0.003, respectively). The median survival time (ST) in the increased-weight group, maintained-weight group, and decreased-weight group was 320, 339, and 222 days, respectively. There was no significant difference in ST among the 3 groups (P = 0.128). In Cox-regression results, weight change group and initial body weight were significant risk factors associated to PFS (P = 0.007, P = 0.001, respectively) while only patient's initial body weight was a significant risk factor to ST (P = 0.013). In conclusion, evaluation of initial body weight and weight changes over time can provide valuable information regarding PFS and ST in dogs with multicentric lymphoma. This article is protected by copyright. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/510798 | ISSN: | 1476-5810 1476-5829 |
DOI: | 10.1111/vco.12637 | SDG/關鍵字: | asparaginase; cyclophosphamide; doxorubicin; prednisolone; vincristine; antineoplastic agent; cyclophosphamide; doxorubicin; prednisone; vincristine; animal experiment; Article; body weight change; cancer chemotherapy; cancer prognosis; clinical outcome; |
顯示於: | 臨床動物醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。